Search research articles
Contact Us
Filters
Showing results (31-40 of 37) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 37 results.
Plos Currents
|
January 25, 2014
A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy
Hugh D Allen, Kevin M Flanigan, Philip T Thrush, et al.
Molecular Therapy. Methods & Clinical Development
|
December 17, 2024
Intrathecal or intravenous AAV9-IDUA/RGX-111 at minimal effective dose prevents cardiac, skeletal and neurologic manifestations of murine MPS I
Lalitha R Belur, Avery K Huber, Hillary Mantone, et al.
Orphanet Journal of Rare Diseases
|
June 15, 2019
Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance
Mehmet Umut Akyol, Tord D Alden, Hernan Amartino, et al.
Orphanet Journal of Rare Diseases
|
May 31, 2019
Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance
Mehmet Umut Akyol, Tord D Alden, Hernan Amartino, et al.
The Canadian Journal of Cardiology
|
December 2, 2024
Factors Associated With Shock at Presentation in Kawasaki Disease Versus Multisystem Inflammatory Syndrome in Children Associated With Covid-19
Supriya S Jain, Ashraf S Harahsheh, Simon Lee, et al.
Pediatric Cardiology
|
May 12, 2025
Systemic Arterial Aneurysms in Kawasaki Disease: An Important Evidence Gap
William B Orr, Marianna Fabi, Michael Khoury, et al.
American Heart Journal
|
June 2, 2020
Expanding the clinical and genetic spectrum of ALPK3 variants: Phenotypes identified in pediatric cardiomyopathy patients and adults with heterozygous variants
Johanna C Herkert, Judith M A Verhagen, Raquel Yotti, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 37) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 37 results.
Plos Currents
|
January 25, 2014
A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy
Hugh D Allen, Kevin M Flanigan, Philip T Thrush, et al.
Molecular Therapy. Methods & Clinical Development
|
December 17, 2024
Intrathecal or intravenous AAV9-IDUA/RGX-111 at minimal effective dose prevents cardiac, skeletal and neurologic manifestations of murine MPS I
Lalitha R Belur, Avery K Huber, Hillary Mantone, et al.
Orphanet Journal of Rare Diseases
|
June 15, 2019
Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance
Mehmet Umut Akyol, Tord D Alden, Hernan Amartino, et al.
Orphanet Journal of Rare Diseases
|
May 31, 2019
Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance
Mehmet Umut Akyol, Tord D Alden, Hernan Amartino, et al.
The Canadian Journal of Cardiology
|
December 2, 2024
Factors Associated With Shock at Presentation in Kawasaki Disease Versus Multisystem Inflammatory Syndrome in Children Associated With Covid-19
Supriya S Jain, Ashraf S Harahsheh, Simon Lee, et al.
Pediatric Cardiology
|
May 12, 2025
Systemic Arterial Aneurysms in Kawasaki Disease: An Important Evidence Gap
William B Orr, Marianna Fabi, Michael Khoury, et al.
American Heart Journal
|
June 2, 2020
Expanding the clinical and genetic spectrum of ALPK3 variants: Phenotypes identified in pediatric cardiomyopathy patients and adults with heterozygous variants
Johanna C Herkert, Judith M A Verhagen, Raquel Yotti, et al.
Page
of 4